Skip to main content

Animations

MJFF Publications

4481 - 4490 of 8826 Results
Title
Year
  • Year
  • 2023
  • 2024
  • 2025
  • 2024
  • 2023
  • 2023
  • 2024
  • 2024
  • 2015
  • 2020
  • Summary Details
    OPEN
    Title: DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease
    Journal Name: Progress in Neurobiology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1016/j.pneurobio.2023.102414
    Citation Count: 18
  • Summary Details
    OPEN
    Title: Psychotropic medication usage in sporadic versus genetic behavioral‐variant frontotemporal dementia
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/alz.14448
    Citation Count: 1
  • Summary Details
    OPEN
    Title: α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000210279
    Citation Count: 24
  • Summary Details
    OPEN
    Title: Sex‐specific mechanisms of cerebral microvascular BK Ca dysfunction in a mouse model of Alzheimer's disease
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/alz.14438
    Citation Count: 3
  • Summary Details
    OPEN
    Title: A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/alz.13319
    Citation Count: 13
  • Summary Details
    OPEN
    Title: Co‐Existent Probable RBD and PD: Disease Progression, Medication Response, and Clinical Trial Implications
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mdc3.13890
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Outcome Selection for Research Studies in Movement Disorders
    Journal Name: Movement Disorders Clinical Practice
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mdc3.14087
    Citation Count: 0
  • Summary Details
    OPEN
    Title: The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons
    Journal Name: Molecular Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s13024-024-00779-9
    Citation Count: 28
  • Summary Details
    OPEN
    Title: Large-scale assessment of polyglutamine repeat expansions in Parkinson disease
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.0000000000002016
    Citation Count: 31
  • Summary Details
    OPEN
    Title: Loss‐of‐Function Variants in HOPS Complex Genes VPS16 and VPS41 Cause Early Onset Dystonia Associated with Lysosomal Abnormalities
    Journal Name: Annals of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1002/ana.25879
    Citation Count: 108
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.